Insider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys $90,895.00 in Stock

Posted by George Bondi on Nov 9th, 2026

Promis Neurosciences (NASDAQ:PMN – Get Free Report) Director Eugene Williams bought 26,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was bought at an average price of $3.43 per share, with a total value of $90,895.00. Following the acquisition, the director directly owned 40,213 shares in the company, valued at $137,930.59. The trade was a 193.25% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Eugene Williams also recently made the following trade(s):

On Friday, October 30th, Eugene Williams bought 1,316 shares of Promis Neurosciences stock. The stock was purchased at an average cost of $3.99 per share, for a total transaction of $5,250.84.

Promis Neurosciences Price Performance

NASDAQ:PMN opened at $4.16 on Monday. The stock’s fifty day moving average is $10.14 and its two-hundred day moving average is $12.75. Promis Neurosciences has a 52 week low of $2.78 and a 52 week high of $27.40. The stock has a market capitalization of $37.32 million, a price-to-earnings ratio of -0.49 and a beta of -0.18.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.10. On average, sell-side analysts expect that Promis Neurosciences will post -5.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Promis Neurosciences

Several institutional investors have recently modified their holdings of PMN. Janus Henderson Group PLC acquired a new stake in shares of Promis Neurosciences in the first quarter valued at $16,418,000. Yu Fan purchased a new position in Promis Neurosciences in the first quarter valued at $4,188,000. Ally Bridge Group NY LLC boosted its holdings in Promis Neurosciences by 66.1% in the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after purchasing an additional 164,880 shares during the period. ADAR1 Capital Management LLC acquired a new position in Promis Neurosciences during the 1st quarter worth $1,211,000. Finally, Seven Fleet Capital Management LP acquired a new position in Promis Neurosciences during the 1st quarter worth $135,000. Institutional investors and hedge funds own 50.13% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on PMN shares. Chardan Capital set a $20.00 target price on Promis Neurosciences and gave the stock a “buy” rating in a research note on Monday, July 27th. Guggenheim reaffirmed a “buy” rating and issued a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings upgraded shares of Promis Neurosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd. Finally, Roth Capital reduced their price target on shares of Promis Neurosciences to $15.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.50.

Check Out Our Latest Research Report on Promis Neurosciences

About Promis Neurosciences

(Get Free Report)

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders.

ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins.